Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M BERGMAN

Showing results (731-740 of 784) with videos related to

Pageof 79
Sort By:
European Urology Focus|May 5, 2020
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer RegistryJessica C L Notohardjo, Malou C P Kuppen, Hans M Westgeest, et al.
Gut|February 18, 2021
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trialGeltrude Mingrone, Annieke Cg van Baar, Jacques Devière, et al.
Nature|February 13, 2009
Population genomics of domestic and wild yeastsGianni Liti, David M Carter, Alan M Moses, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
Endoscopy|April 13, 2013
Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter studyF G I van Vilsteren, L Alvarez Herrero, R E Pouw, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 3, 2020
Endoscopic Resection Without Subsequent Ablation Therapy for Early Barrett's Neoplasia: Endoscopic Findings and Long-Term MortalityS N van Munster, E A Nieuwenhuis, B L A M Weusten, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 8, 2021
Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvementM J van der Wel, E Klaver, R E Pouw, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Gut|June 25, 2015
Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort studyMargriet R Timmer, Pierre Martinez, Chiu T Lau, et al.
Pageof 79

Showing results (731-740 of 784) with videos related to

Sort By:
Pageof 79
European Urology Focus|May 5, 2020
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer RegistryJessica C L Notohardjo, Malou C P Kuppen, Hans M Westgeest, et al.
Gut|February 18, 2021
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trialGeltrude Mingrone, Annieke Cg van Baar, Jacques Devière, et al.
Nature|February 13, 2009
Population genomics of domestic and wild yeastsGianni Liti, David M Carter, Alan M Moses, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
Endoscopy|April 13, 2013
Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter studyF G I van Vilsteren, L Alvarez Herrero, R E Pouw, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 3, 2020
Endoscopic Resection Without Subsequent Ablation Therapy for Early Barrett's Neoplasia: Endoscopic Findings and Long-Term MortalityS N van Munster, E A Nieuwenhuis, B L A M Weusten, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 8, 2021
Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvementM J van der Wel, E Klaver, R E Pouw, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Gut|June 25, 2015
Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort studyMargriet R Timmer, Pierre Martinez, Chiu T Lau, et al.
Pageof 79